Background Cancer refers to a group of some of the worldwide most diagnosed and
deadliest pathophysiological conditions that conquered researchers' attention for decades …

Simple Summary Resistance to tamoxifen treatment is an obstacle for ER+ ve breast cancer
therapy. The overexpression of c-MYC is a known driver of cancer progression and is …

Cancer genomes from patients with African (AFR) ancestry have been poorly studied in
clinical research. We leverage two large genomic cohorts to investigate the relationship …

Background Patients with stage II to III breast cancer have a high recurrence rate. The early
detection of recurrent breast cancer remains a major unmet need. Circulating tumor DNA …

Molecular markers have been used as a tool for diagnostic approaches, staging, and
evaluation of therapeutic responses in patients with cancer. Cancer molecular markers can …

Abstract Background African American women experience a twofold higher incidence of
triple-negative breast cancer (TNBC) and are 40% more likely to die from breast cancer than …

Globally, breast cancer is the second leading cause of cancer-related mortality among
women, with approximately 1.4 million new cases diagnosed annually. Associated genetic …

Breast cancer (BCa) is a major global health challenge. The BCa genome often carries
extensive somatic copy number alterations (CNAs), including gains/amplifications and …

MYC amplification and overexpression in breast cancer occur 16% and 22%, respectively,
and MYC has a linchpin role in breast carcinogenesis. Emerging evidence has started to …

PURPOSE In lung squamous cell carcinoma (LUSC), Black patients show significantly
higher incidence and lower overall survival than White patients. Although socioeconomic …